Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
202132 citationsJournal Articlehybrid Open Access
Field-Weighted Citation Impact: 3.53
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer | Researchclopedia